Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was valued at USD 2.15 billion in 2024 and is projected to reach USD 3.95 billion by 2034, expanding at a CAGR of 6.1%

Market Overview
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was valued at USD 2.15 billion in 2024 and is projected to reach USD 3.95 billion by 2034, expanding at a CAGR of 6.1% during the forecast period.
CIDP is a rare autoimmune neuropathy marked by progressive weakness, sensory loss, and impaired motor function due to demyelination of peripheral nerves. Rising disease awareness, improved diagnostic techniques, and increasing availability of immunomodulatory therapies are major contributors to market growth.

Demand for intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), corticosteroids, plasma exchange therapy, and emerging biologics continues to increase. Growing focus on early diagnosis and long-term management is further strengthening the market outlook.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71898

Market Dynamics
Drivers
• Increasing global awareness and improved recognition of CIDP among neurologists and primary care physicians.
• Growing adoption of IVIG and SCIG as first-line treatments for CIDP.
• Advancements in nerve conduction studies, electromyography (EMG), and imaging improving diagnostic accuracy.
• Expansion of plasma-derived therapies and improved immunoglobulin production capacity.
• Rising prevalence of autoimmune disorders globally.

Restraints
• High cost of IVIG and SCIG therapies, creating financial burden in many regions.
• Limited access to neurologists and infusion centers in low-income countries.
• Treatment variability and lack of standardized diagnostic criteria leading to underdiagnosis or misdiagnosis.
• Long-term therapy dependence poses adherence challenges.

Opportunities
• Development of next-generation biologics and monoclonal antibodies targeting autoimmune neuropathy pathways.
• Increasing adoption of home-based SCIG therapy improving convenience and long-term adherence.
• AI-enabled diagnostic tools for early identification of demyelinating neuropathies.
• Expansion of patient registries and real-world evidence databases supporting better care guidelines.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71898/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

Market Growth Outlook (2024-2034)
The CIDP market will grow from USD 2.15 billion in 2024 to USD 3.95 billion in 2034, driven by strong demand for immunoglobulin therapies, improved infusion technologies, and expanding access to neuromuscular care worldwide.
Emerging biologics and non-immunoglobulin therapies are expected to significantly influence market dynamics over the next decade.

Segmentation Analysis
By Treatment Type
Intravenous immunoglobulin (IVIG) remains the gold standard therapy, offering rapid improvement in strength and neurological function.
Subcutaneous immunoglobulin (SCIG) is increasingly preferred for long-term maintenance due to home-based administration and improved quality of life.
Corticosteroids (e.g., prednisone) provide an effective and cost-efficient option for many patients, especially in early disease stages.

Plasma exchange (plasmapheresis) is used for refractory cases or rapid symptomatic relief.
Emerging biologics and immunomodulators (e.g., anti-FcRn agents) are under active development and expected to broaden future treatment options.

By Diagnosis
Diagnosis involves nerve conduction studies (NCS), EMG, cerebrospinal fluid analysis, and clinical evaluation of progressive neuropathy symptoms.
High-resolution nerve ultrasound and MRI neurography are gaining adoption for detailed nerve assessments.
As awareness increases, earlier diagnosis is improving treatment outcomes.

By End User
Hospitals administer acute care, IVIG infusions, and advanced diagnostics.
Neurology clinics manage long-term CIDP therapy, follow-up, and rehabilitation.
Home-care settings are increasingly used for SCIG and maintenance IVIG infusions.
Specialized infusion centers support ongoing treatment administration.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71898

Regional Insights
North America
North America dominates the CIDP market due to high diagnosis rates, advanced neuromuscular care infrastructure, widespread adoption of IVIG/SCIG, and strong reimbursement systems. The U.S. accounts for the largest global share.

Europe
Europe holds a major share driven by early diagnosis programs, structured neuromuscular clinics, and widespread use of plasma-derived therapies. Countries like Germany, France, and the UK lead in CIDP therapy adoption.

Asia Pacific
Asia Pacific is the fastest-growing region, fueled by increasing autoimmune disease prevalence, improved healthcare access, and rising investment in diagnostic neurology. Japan, China, India, and South Korea show strong growth potential.

Latin America & Middle East/Africa
These regions show gradual market expansion due to improving neurology services and growing awareness, though treatment costs and limited infusion capacity remain challenges.

Competitive Landscape
The CIDP market includes immunoglobulin manufacturers, biotech innovators, and neurology-focused pharmaceutical companies.

Key Companies Include:
• CSL Behring
• Grifols
• Takeda Pharmaceutical
• Octapharma
• Pfizer
• Kedrion Biopharma
• Shire (Takeda)
• Teva Pharmaceutical Industries
• Biogen
• Argenx
These companies focus on immunoglobulin production, next-generation biologics, FcRn inhibitors, and improved neuromuscular diagnostics.

Recent Developments
• Growing global demand and production expansion for IVIG and SCIG therapies.
• Advancements in FcRn inhibitors showing promise in clinical trials for autoimmune neuropathies.
• Increased adoption of home-based immunoglobulin administration improving patient convenience.
• Expanded use of nerve ultrasound for CIDP diagnosis and monitoring.
• Rising investment in patient registries improving real-world disease understanding.

This report is also available in the following languages : Japanese (慢性炎症性脱髄性多発神経炎(CIDP)市場), Korean (만성 염증성 탈수초성 다발신경병증(CIDP) 시장), Chinese (慢性炎症性脱髓鞘性多发性神经病(CIDP)市场), French (Marché de la polyneuropathie inflammatoire démyélinisante chronique (PIDC)), German (Markt für chronisch-entzündliche demyelinisierende Polyneuropathie (CIDP)), and Italian (Mercato della polineuropatia demielinizzante infiammatoria cronica (CIDP)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71898

Our More Reports:

Synovial Sarcoma (SS) Market
https://exactitudeconsultancy.com/reports/71613/synovial-sarcoma-ss-market

Ovarian Cancer Market
https://exactitudeconsultancy.com/reports/71615/ovarian-cancer-market

Gastroesophageal Junction Adenocarcinoma Market
https://exactitudeconsultancy.com/reports/71617/gastroesophageal-junction-adenocarcinoma-market

Lupus Nephritis Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71619/lupus-nephritis-patient-pool-analysis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.